Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07569159Phase 2Not Yet Recruiting

MDMA Therapy in Veterans With PTSD

Role: lead

NCT05947383Phase 2Active Not Recruiting

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

Role: lead

NCT06902974Phase 2Recruiting

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

Role: lead

NCT05584826Phase 2Recruiting

MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other

Role: lead

All 4 trials loaded